La cadena de opciones muestra datos clave de las opciones de acciones de Arcutis Biotherapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Arcutis Biotherapeutics..

Arcutis Biotherapeutics (NASDAQ:ARQT) Bolsa, Cadena de Opciones

ARCUTIS BIOTHERAPEUTICS INC

Arcutis Biotherapeutics

Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ARQT

ATPC

BDTX

DRCT

GCTK

ITCI

LAES

LDTC

QBTS

QMMM

RGTI

RIME

SAGE

STAI

TRAW

VMAR

Sage Therapeutics sube 34% tras oferta de Biogen. Conoce los mayores ganadores y perdedores del premercado de EE.UU.

Las acciones de Sage Therapeutics (SAGE) se disparan un 34%; 20 acciones que se mueven en premercado

Arcutis Biotherapeutics, Inc. - Common stock

Arcutis Biotherapeutics Inc

Health Care

Press Releases

Arcutis to Present New Long-Term Results of ZORYVE® (roflumilast) Cream at the 2025 Revolutionizing Atopic Dermatitis Conference

Management

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Arcutis Enrolls First Child in INTEGUMENT-INFANT Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis

General

Arcutis' ZORYVE® (roflumilast) Cream 0.15% Receives Strong Recommendation in American Academy of Dermatology Updated Guidelines for Adult Atopic Dermatitis

Arcutis to Report Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025

Frazier Life Sciences Closes Oversubscribed $1.3 Billion Venture Fund

Earnings

Arcutis Announces Second Quarter 2025 Financial Results and Provides Business Update

Arcutis to Present at Upcoming Investor Conferences

MIRM

NAMS

TARS

Agios Pharmaceuticals, Inc. - Common Stock

Agios Pharmaceuticals

Apogee Therapeutics

Aurinia Pharmaceuticals Inc - Common Shares

Aurinia Pharmaceuticals

BioCryst Pharmaceuticals, Inc. - Common Stock

BioCryst Pharma

Beam Therapeutics

Biohaven

Cidara Therapeutics

Celcuity

CG Oncology

Cogent Biosciences

Denali Therapeutics

Dyne Therapeutics

Galapagos NV - American Depositary Shares

Galapagos

ImmunityBio

IDEAYA Biosciences

Immunocore Holdings plc - American Depositary Shares

Immunocore Holdings

Disc Medicine

Mesoblast Limited - American Depositary Shares

Mesoblast

Anbio Biotechnology - Class A Ordinary Shares

Anbio Biotechnology

Recursion Pharmaceuticals, Inc. - Class A Common Stock

Recursion Pharmaceuticals

Sarepta Therapeutics, Inc. - Common Stock

Sarepta Therapeutics

Travere Therapeutics, Inc. - Common Stock

Travere Therapeutics

Twist Bioscience Corporation - Common Stock

Twist Bioscience

Vericel

Viridian Therapeutics, Inc. - Common Stock

Viridian Therapeutics

Needham

Goldman Sachs

HC Wainwright & Co.

Jefferies

Comments

Arcutis Biotherapeutics

Arcutis Biotherapeutics (ARQT) Opciones

Arcutis Biotherapeutics (NASDAQ:ARQT) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL